Evidence map›Paper›PMID 40816471›Full record

ArticleThe Journal of biological chemistry2025

Mechanism of inhibition of acid-mediated transthyretin aggregation by designed peptides.

Xun Sun, Rose Pedretti, H Jane Dyson, Lorena Saelices, Peter E Wright

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xun SunDepartment of Integrative Structural and Computational Biology and Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.
Rose PedrettiCenter for Alzheimer's and Neurodegenerative Diseases, Department of Biophysics, Peter O'Donnell Jr Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
H Jane DysonDepartment of Integrative Structural and Computational Biology and Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.
Lorena SaelicesCenter for Alzheimer's and Neurodegenerative Diseases, Department of Biophysics, Peter O'Donnell Jr Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Peter E WrightDepartment of Integrative Structural and Computational Biology and Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, California, USA. Electronic address: wright@scripps.edu.

Funding

Molecular mechanisms of transthyretin amyloidosisR01DK124211 · NIDDK · SCRIPPS RESEARCH INSTITUTE, THE · PI PETER Edwin WRIGHT · 2020 to 2026
$3.0M
Closing the gap between structural biology and translational science for amyloid diseasesDP2HL163810 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SAELICES GOMEZ, LORENA · 2021 to 2024
$2.5M
American Heart Association-American Stroke Association 17POST32810003American Heart Association-American Stroke Association 20POST35050060NHLBI NIH HHS DP2 HL163810NIDDK NIH HHS R01 DK124211
6 · The paper itself

Abstract

Aggregation of transthyretin (TTR) causes TTR cardiomyopathy and polyneuropathy through amyloidosis. To initialize TTR aggregation, the native TTR tetramer first dissociates to a monomeric intermediate, which misfolds and self-assembles to oligomers, eventually forming insoluble aggregates and fibrils. Peptide inhibitors have been designed to cap two β-strands that are buried in the well-folded tetramer but are solvent-exposed in the monomeric aggregation intermediate. However, how these peptides affect the reaction kinetics of individual steps in the multi-step TTR aggregation pathway remains unknown. Here, we integrated

Indexed as

PeptidesPrealbuminProtein AggregatesHumansHydrogen-Ion ConcentrationKineticsPeptidesPrealbuminProtein AggregatesTTR protein, humanaggregation inhibitoraggregation kineticsaggregation mechanismamyloidreal-time (19)F-NMRtransthyretin aggregation

Identifiers

PMID40816471
PMCPMC12624794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.